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Abstract
Introduction: Co-morbidity and mortality due to cardiovascular disease (CVD) are increased in patients with
rheumatoid arthritis (RA). Most published studies in this field are retrospective or cross sectional. We investigated
the presence of traditional and disease related risk factors for CVD at the onset of RA and during the first five years
following diagnosis. We also evaluated their potential for predicting a new cardiovascular event (CVE) during the
five-year follow-up period and the modulatory effect of pharmacological treatment.
Methods: All patients from the four northern-most counties of Sweden with early RA are, since December 1995,
consecutively recruited at diagnosis (T0) into a large survey on the progress of the disease. Information regarding
cardiovascular co-morbidity and related predictors was collected from clinical records and supplemented with
questionnaires. By April 2008, 700 patients had been included of whom 442 patients had reached the five-year
follow-up (T5).
Results: Among the 442 patients who reached T5 during the follow-up period, treatment for hypertension increased
from 24.5 to 37.4% (P < 0.001)), diagnosis of diabetes mellitus (DM) from 7.1 to 9.5% (P < 0.01) whilst smoking
decreased from 29.8 to 22.4% (P < 0.001) and the BMI from 26.3 to 25.8 (P < 0.05), respectively. By T5, 48 patients had
suffered a new CVE of which 12 were fatal. A total of 23 patients died during the follow-up period. Age at disease
onset, male sex, a previous CVE, DM, treatment for hypertension, triglyceride level, cumulative disease activity (area
under the curve (AUC) disease activity score (DAS28)), extra-articular disease, corticosteroid use, shorter duration of
treatment with disease modifying anti-rheumatic drugs (DMARDs) and use of COX-2 inhibitors increased the hazard
rate for a new CVE. A raised erythrocyte sedimentation rate (ESR) at inclusion and AUC DAS28 at six months increased
the hazard rate of CVE independently whilst DMARD treatment was protective in multiple Cox extended models
adjusted for sex and CV risk factors. The risk of a CVE due to inflammation was potentiated by traditional CV risk factors.
Conclusions: The occurrence of new CV events in very early RA was explained by traditional CV risk factors and
was potentiated by high disease activity. Treatment with DMARDs decreased the risk. The results may have
implications for cardio-protective strategies in RA.
Introduction
Mortality due to cardiovascular disease (CVD) is
increased in patients with rheumatoid arthritis (RA)
[1-8]. Several studies confirmt h a ta l s oc a r d i o v a s c u l a r
(CV) morbidity is increased in patients with RA
compared with controls [5,7-11]. According to most
previous reports, traditional risk factors for CVD cannot
fully explain this fact [3,5,10,12,13]. We have previously
reported morbidity and case fatality due to myocardial
infarction (MI) to be increased in patients with estab-
lished RA from Northern Sweden, compared with the
general population [9]. Hypertension was the only tradi-
tional CV risk factor that clearly predicted a CVE [9,13].
Although some controversy may exist over the
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as being predictive of CVD in patients with RA
[13,15,16] and appears to potentiate the effect of tradi-
tional CV risk factors [17]. Most published studies in
this field are, however, retrospective or cross sectional,
and are often hospital-based and comprise information
from medical records and various registers. Such studies
are occasionally subject to deficiencies; for example,
patients with low disease activity, patients moving out of
the study region, and those suffering a premature death
are lost. In order to focus on the progression of CVD
during the course of a rheumatoid disease and to evalu-
ate related risk factors in early RA, a prospective design
is necessary.
The present observational study was designed to fol-
low patients with early RA prospectively from disease
onset. The aim was: first, to investigate the presence of
traditional and disease related CV risk factors, at the
onset of RA and during the first five years following
diagnosis, in a large cohort of patients; second, to evalu-
ate prospectively the predictive effect of these factors for
CVD, as measured by the first CVE during follow-up;
and finally, to assess the potential modulating effect(s)
of the prescribed pharmacological treatment.
Materials and methods
By reference to the nation-wide Swedish Rheumatoid
Arthritis Registry [18] all eligible patients from the four
northern-most counties of Sweden diagnosed with early
RA (that is, symptomatic for <12 months), and fulfilling
the American Rheumatism Association classification cri-
teria [19] are since December 1995 consecutively
included in a large survey on the progress of RA and
development of co-morbidity, in particular CVD. By
April 2008, 700 patients (481 women, 219 men) regis-
tered with newly diagnosed early RA had been included
in the study at diagnosis of RA (baseline, T0). Of these,
442 patients reached T5, that is, they had suffered their
disease for more than five years. All patients had been
assessed regularly by their local rheumatologist during
the follow-up period with special attention to estab-
lished CV risk factors, any previous CVE, and clinical
examination including blood pressure and laboratory
tests. The following parameters were recorded at base-
line and after 6, 12, 18, 24, 36, and 60 months: the 28-
joint count of tender and swollen joints; a visual analo-
gous scale (VAS) for pain and patient’s global assess-
ment; completion of a Health Assessment Questionnaire
(HAQ) [20] and inflammatory markers, that is, erythro-
cyte sedimentation rate (ESR) and C-reactive protein
(CRP). Disease activity score (DAS28) [21] was calcu-
lated. Lipid levels (total cholesterol (mmol/L), high-den-
sity lipoprotein (HDL, mmol/L) and triglycerides
(mmol/L)) were analysed in the majority of cases at
baseline, otherwise as soon as possible during the fol-
low-up period. The presence of autoantibodies, that is,
rheumatoid factor (RF), and anti-nuclear antibodies
(ANA), was detected at baseline by the routine methods
at each hospital. Antibodies against cyclic citrullinated
peptides/proteins (ACPA) were analysed at baseline
using enzyme-linked immunoassays (ELISA) for anti-
CCP antibodies type 2. Genotyping for PTPN22 1858C/
T polymorphisms was performed for the majority of the
patients using the 5’ -nuclease assay [22,23] and for
HLA -DRB1 using polymerase chain reaction sequence-
specific primers from a DR low-resolution kit and
DRB1*04 sub-typing kit (Dynal, Oslo, Norway) as
described previously [24]. In the present work the
shared epitope (SE) alleles were defined as HLA-
DRB1*0401 or DRB1*0404.
All patient records were carefully read and data col-
lected according to a study protocol, both at inclusion
at T0 and after five years at T5. In addition, the patients
completed a self-reported questionnaire on co-morbidity
at T0 and at T5 to further increase the validity of the
collected data. Recorded variables were: all co-morbidity
including previous CVE, that is, prior to inclusion, and
new CVE during follow-up, that is, myocardial infarction
(MI)/coronary artery bypass grafting (CABG), stroke/
transient ischaemic attack (TIA)/deep vein thrombosis
(DVT)/pulmonary embolism (PE), and ruptured aortic
aneurysm. Myocardial infarction was recorded when the
diagnosis had been made according to the World Health
Organization (WHO) criteria [25]. A cerebrovascular
lesion was recorded when intra-cerebral haemorrhage or
cerebral infarction had been diagnosed by either compu-
terized tomography or magnetic resonance imaging, or
when a typical clinical profile of neurological deficits
had persisted for more than 24 h. A TIA was recorded
in cases when the focal neurological deficit of presumed
ischaemic origin had persisted for less than 24 h. Deep
vein thrombosis/pulmonary embolism was recorded
when the diagnosis had been verified objectively (by
phlebography, sonography, scintigraphy, and/or arterio-
graphy), or when the clinical signs combined with pul-
monary radiography, electrocardiography, and laboratory
changes resulted in full time warfarin treatment. The
information regarding fatal cardiovascular events was
obtained from the National Board of Health and Wel-
fare. Furthermore, traditional CV risk factors (ongoing
treatment for hypertension and current blood pressure,
diabetes mellitus (DM), smoking (current and previous),
body mass index (BMI)), rheumatoid nodules and time
for development of extra-articular disease (EAD) [26]
were registered. Cumulated pharmacological treatment
was registered (months before inclusion and during fol-
low-up) regarding corticosteroids and disease modifying
anti-rheumatic drugs (DMARDs, that is, methotrexate,
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mophetil, myocrisine, auranofin, cyclosporine, lefluno-
mid, alkylating cytotoxic agents) including biological
agents (etanercept, adalimumab, infliximab, anakinra,
rituximab) at inclusion and at follow-up. Treatment
with non-steroidal anti-inflammatory drugs (NSAIDs),
before inclusion (T0) and any period during the follow-
up period (T5) was registered as “yes” or “no”,a sw a s
treatment with statins - regarded as a proxy for presence
of hyperlipidaemia. Time for treatment with selective
cyclo-oxygenase-2 (COX-2) inhibitors was registered as
exact as possible.
The first 128 patients included from two of the coun-
ties fulfilled the criteria for inclusion in the Swedish
RA-registry but were, due to a lack of personnel
resources, not recorded regularly. These patients were
followed up in the same way as the other patients
regarding base line data on inflammatory variables,
autoantibodies, SE, pharmacological treatment, CV risk
factors and previous and new CV events; however, they
lack regularly recorded data on laboratory results, VAS
scales and joint counts during the follow-up period.
These patients did not differ significantly from the rest
of the cohort when comparing ESR at baseline.
The regional Ethics Committee at the University Hos-
pital of Umeå approved this study and all participants
gave their written informed consent in accordance with
the Declaration of Helsinki.
Statistical analysis
The integral of disease activity, DAS28, was calculated
in order to evaluate the total burden of disease activity
over time and is referred to as the area under the curve
(AUC) of DAS28 at 6, 12 and 24 months after inclusion
into the study. When RA register data were missing, the
last value was used to impute data once for each para-
meter assessed. Furthermore, for the regression analyses,
imputations were made as follows: for AUC DAS28 at 6,
12 and 24 months respectively, the patient sample was
divided into two groups, that is, censored and uncen-
sored patients. Patients were censored after the time of
the first event after inclusion or death or end of study.
When values were missing for a single patient in each
group respectively, data values were assigned by simple
random sampling with replacement of values from
patients with non-missing values, thus each missing
value was replaced with an observed value. The same
method was used for censored patients lacking data on
levels of triglycerides.
For comparison of means of data and proportions
between two sub-groups, unpaired t-test and Chi-
squared tests were used, respectively. For comparison of
recurrent data in the same individuals between variables
at baseline (T0) and those collected at follow-up (T5),
paired t-tests and McNemar’s test for binary data were
used.
For the regression analyses, time dependent variables
were created for some variables: for extra articular dis-
ease (EAD), the variable time-EAD indicates when EAD
occurred and time t w h e naC V Eo rac e n s o r i n gh a s
occurred. A dichotomous time-varying covariate was
defined, with the value at time t =1i f( t >time-EAD),
otherwise this covariate was = 0. For treatment with
corticosteroids and COX-2 inhibitors, dichotomous
time-dependent variables were defined in a similar way.
When defining the time-dependent variable for
DMARDs, the accumulated number of months of
DMARD treatment was also used; at each time t of an
event and for every patient in the risk set, we deter-
mined the composition of the risk set and calculated the
actual value of the variable DMARD at time t (DMARD
(t)). For AUC DAS28, the time-dependent covariate
AUC DAS28 was assumed to follow a step-function in
which the values for AUC DAS6, AUC DAS12, and
AUC DAS24 remained throughout the time intervals (0,
12), (12, 24) and (24, 60), respectively.
Cox proportional hazard simple regression models
with fixed (time-independent) covariates were used to
identify covariates associated with the first new CVE in
the group of patients that were followed-up for five
years following diagnosis (n = 442). For time dependent
covariates, Cox extended models were also used with
time-varying variables in simple regression models and
in combined regression models with both fixed and
time-dependent variables. Covariates reflecting disease
activity, traditional risk factors for CVD and pharmaco-
logical treatment were considered in multiple regression
modelling, based on clinical experience, previous studies
and with statistical significance (P <0 . 2 )i ns i m p l eC o x
models, and tested in a few appropriate combined
models.
All calculations were performed using PASW Statistics
18.0 (SPSS, Chicago, IL, USA).
Results
In all, 700 early RA patients were attending the four
rheumatology centres between December 1995 and
April 2008. The first follow-up was in each case made
five years after inclusion (T5); by April 2008, 442
patients had reached the five-year follow-up (T5).
Twenty- three patients had died within the first five
years following inclusion. All patients could be traced at
the follow-up.
Demographic data at T0 and T5 (Table 1)
Descriptive data for all patients at baseline (T0) (n =
700) and for those having reached T5 (n = 442) are pre-
sented in Table 1. The mean age (standard deviation,
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(14.3) years; for women this value was 53.7 (14.8) and
for men 58.6 (12.6) years. The mean duration from the
first signs of disease symptoms to inclusion at T0 was
6.6 (3.3) months, and was the same in both sexes.
Regarding demographic data, the patient group that had
reached T5 (n = 442) did not differ from the whole
patient group (n = 700) at baseline. In the patient group
that was followed up at T5 (n = 442), all of the variables
reflecting disease activity( t h a ti s ,E S R ,C R P ,D A S 2 8 )
had decreased significantly (P < 0.001 for all three para-
meters) compared with baseline. The number of tender
and swollen joints, HAQ, VAS pain and VAS global had
also decreased significantly (P < 0.001 for all).
At the five-year follow-up (T5), 48 of the 442 patients
(27 men, 21 women) (10.9%) had experienced a new
CVE: 15 MI, 4 CABG, 23 stroke/TIA, 5 DVT/LE and 1
ruptured aortic aneurysm. Twelve of the events were
fatal. In all, 23 of the 442 patients died from various
causes during the follow-up period. Fifteen of the 48
patients who had experienced a new CVE had suffered
an event prior to inclusion.
Traditional CV risk factors at T0 and at T5
Data on traditional CV risk factors at baseline and after
five years are shown in Table 2. In patients who had
reached T5 (n = 442), treatment for hypertension had
increased (P <0 . 0 0 1 )c o m p a r e dw i t hT 0 ,a n db o t hs y s -
tolic and diastolic blood pressure had decreased signifi-
cantly (P < 0.01 for both). The proportion of patients
Table 1 Demographic and clinical data in early RA at
baseline (T0) and after five years (T5)
Variables T0 (n = 700) T5 (n = 442)
Sex, f/m 481/219 301/141
Age at onset of symptoms (years) 55.2 (14.3) 55.1 (14.2)
Duration of symptoms at inclusion (mo) 6.6 (3.3) 6.7 (3.2)
RF, n (%) 489 (76.4) na
ANA, n (%) 130 (25.0) na
Anti-CCP, n (%) 373 (67.8) na
SE, n (%) 330 (56.9) na
PTPN22 Tvariant, n (%) 167 (34.0) na
ESR (mm) 31.5 (23.7) 20.0 (19.9)***
CRP (mg/l) 22.0 (24.6) 11.1 (14.3)***
DAS28
1 4.8 (1.4) 3.2 (1.3)***
HAQ
1 0.9 (0.6) 0.6 (0.52)***
Tender joints
1 6.7 (5.8) 2.6 (3.7)***
Swollen joints
1 7.4 (5.2) 3.2 (4.1)***
VAS pain (mm)
1 44.5 (25.2) 28.7 (20.7)***
VAS global (mm)
1 45.3 (24.9) 29.8 (20.6)***
AUC DAS28 (6 mo)
1,2 - 25.8 (7.1)
AUC DAS28 (12 mo)
1,2 - 47.2 (13.5)
AUC DAS28 (24 mo)
1,2 - 87.5 (26.0)
Extra-articular disease, n (%)
3 - 21 (3.0)
Presence of nodules, n (%) - 78 (20.7)
Mean (S.D.) or n (%).
*** P < 0.001, ** P < 0.01, paired t-test, for all patients who had reached the
five-year follow-up, that is, who had data at both baseline (T0) and at follow-
up (T5). NA, not analysed
1 Regularly collected data from the RA-registry for 314 patients.
2 AUC for DAS28 6, 12 and 24 months after inclusion.
3 Criteria used for severe extra-articular manifestations: pericarditis, pleuritis,
interstitial lung disease, Felty’s syndrome, neuropathy, scleritis/episcleritis,
glomerulonephritis, major cutaneous vasculitis and vasculitis involving other
organs [26]. RA, rheumatoid arthritis; RF, rheumatoid factor; ANA, anti-nuclear
antibodies; Anti-CCP, anti-cyclic citrullinated peptide/protein; SE, shared
epitope; PTPN22, protein tyrosine phosphatise nonreceptor type 22; ESR,
erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, disease
activity score; HAQ, Health Assessment Questionnaire; VAS, visual analogous
scale; AUC, area under the curve.
Table 2 Cardiovascular risk factors and treatment in early
RA at baseline (T0) and after five years (T5)
Variables T0 (n = 700) T5 (n = 442)
Hypertension, n (%) 170 (24.5) 164 (37.4)***
BP systolic, mmHg 144.1 (22.6) 141.2 (21.8)**
BP diastolic, mmHg 82.7 (10.3) 81.0 (9.6)**
Diabetes mellitus, n (%) 48 (7.1) 41 (9.5)**
BMI 26.3 (4.5) 25.8 (4.3)*
Smoking, present, n (%) 196 (29.8) 92 (22.4)***
Smoking, ever, n (%) 451 (69.5) -
Previous CVE, n (%) 72 (10.4) -
s-Cholesterol, mmol/L 5.6 (1.1)
1 na
s-HDL, mmol/L 1.5 (0.5)
1 na
s-Triglycerides, mmol/L 1.5 (0.7)
1 na
Statin treatment, n (%) 54 (8.1) 71 (16.4)***
NSAIDs, n (%) 386 (58.5) 357 (82.4)***
COX-2 inhibitors, n (%) 82 (12.3) 112 (25.7)***
Corticosteroids, ever, n (%) 197 (29.1) 367 (72.7)***
Corticosteroids, months (T0 to T5) - 22.3 (24.0)
DMARDs ≤3 months after inclusion, n (%) - 393 (88.9)
DMARDs, ever, n (%) - 429 (96.8)
DMARDs months (T0 to T5) - 51 (16.4)
Methotrexate ever, n (%) - 361 (81.5)
Biologicals, ever, n (%) - 62 (14.2)
Mean (SD) or n (%).
*** P < 0.001, ** P < 0.01, * P < 0.05, paired t-test, for all patients who had
reached the five-year follow-up, that is, who had data at both baseline (T0)
and at follow-up (T5). na, not analysed
1analysed at baseline or as soon as possible during follow-up
BMI, Body mass index; BP, blood pressure; COX-2, cyclo-oxygenase-2; CVE,
cardiovascular event; DMARDs, disease-modifying anti-rheumatic drugs; HDL,
high-density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; RA,
rheumatoid arthritis
Innala et al. Arthritis Research & Therapy 2011, 13:R131
http://arthritis-research.com/content/13/4/R131
Page 4 of 10with type II diabetes had increased (P < 0.01). Signifi-
cantly fewer patients were smokers (P < 0.001). BMI
had also decreased significantly between T0 and T5 (P <
0.05).
Pharmacological treatment at T0 and at T5
Data on pharmacological treatment are shown in Table
2. A total of 393 patients (88.9%) were prescribed
DMARDs within three months following inclusion (T0)
into the study. The mean time between the first symp-
toms of disease and DMARD treatment was 7.0 (0.3)
months. During the first five years of disease, the
patients had been treated with DMARDs for a mean
duration of 51 (16.4) months. At T5, 429 (96.8%) of the
patients were taking, or had been treated with,
DMARDs for some time; 361 (81.5%) had received
methotrexate, and 62 (14.2%) had been treated with bio-
logical agents.
Predictors for a new CVE
In the evaluation of predictors of cardiovascular disease,
simple Cox models revealed that an increase in the
hazard rate of a new CVE during the follow-up period
was predicted by higher cumulative disease activity (that
is, both AUC of DAS28 at six months, and measured as
a time dependent variable) and by progression of extra-
articular disease, in addition to a greater age at disease
onset, being male, having had a previous CVE and to
traditional cardiovascular risk factors (diabetes mellitus,
treated hypertension, higher triglyceride level).
Regarding pharmacological treatment, simple Cox
models showed that a new CVE during follow-up was
predicted by shorter duration of treatment with
DMARDs during follow-up and treatment with corticos-
teroids both at/or before inclusion (T0) and during fol-
low-up, before a new CVE. Also treatment with COX-2
inhibitors before CVE increased the risk in simple regres-
sion analysis. Treatment with DMARDs within three
months of disease onset was protective, analogous to
total treatment with DMARDs before a CVE (Table 3).
The presence of ACPAs, RF, ANA, HLA-SE defined as
*0404, *0401 in the present work, and PTPN22-T poly-
morphism had no statistically significant impact on the
incidence of CVE.
When the impact of disease activity was evaluated in a
multiple Cox model and adjusted for gender, hyperten-
sion and triglyceride level, a higher ESR at baseline inde-
pendently increased the hazard rate of a new CVE.
Treatment with DMARDs was protective, when
included in the model above (Table 4). Adding age to
the model resulted in a P-value = 0.19 for age. There
were no significant interactions in the model. Figure 1
illustrates how the hazard ratio of a new CVE is poten-
tiated by the combination of inflammatory activity (ESR)
Table 3 Co-variates for a new cardiovascular event
during five years after RA-onset in 442 patients.
Co-variates HR CI 95% P-
value
Sex f/m 0.314/f 0.177, 0.557 0.001
Age at onset of RA 1.060/yr 1.035, 1.086 <0.001
Diabetes mellitus 2.893/+ 1.297, 6.452 <0.01
Hypertension, treated 4.066/+ 2.308, 7.162 <0.001
BP, syst 1.015/mmHg 1.003, 1.026 <0.05
BP, diast 1.033/mmHg 1.003, 1.063 <0.05
S-HDL-chol 0.318/mmolL
-
1
0.090, 1.123 = 0.075
S-Triglycerides 1.919/mmolL
-
1
1.461, 2.521 <0.001
Statin treatment 2.237/+ 0.950, 5.270 = 0.065
Previous CVE 5.912/+ 3.210,
10.891
<0.001
AUC DAS28 (6 mo) 1.063 1.021, 1.106 <0.01
AUC DAS28
1 1.025 1.010, 1.040 <0.01
Extra-articular disease
1 3.343/+ 1.421, 7.867 <0.01
Corticosteroids at/before
inclusion
1.030/mo 1.004, 1.056 <0.05
Corticosteroids
1 2.243/+ 1.208, 4.164 <0.05
DMARDs within 3 mo
2 0.402/+ 0.200, 0.808 <0.05
DMARDs
1 0.885/mo 0.200, 0.808 <0.001
COX-2-inhibitors
1 2.392/+ 1.206, 4.744 <0.05
Results of Simple Cox proportional hazards regression models, with fixed and
time-dependent co-variates.
1 = Time-dependent co-variate
2DMARD treatment started within three months from baseline (T0).
AUC, area under the curve; BP, blood pressure; CI, confidence interval; COX-2,
cyclo-oxygenase-2; CVE, cardiovascular event; DAS28, disease activity score;
DMARD, disease-modifying anti-rheumatic drug; HDL, high-density lipoprotein;
HR, hazard ratio; RA, rheumatoid arthritis
Table 4 Importance of potential risk factors for a new
CVE in early- RA followed for five years.
Co-variates HR CI 95% P-value
ESR, baseline 1.018/+ 1.005, 1,030 <0.01
Triglycerides 1.853/mmolL
-1 1.376, 2.496 <0.001
Hypertension 2.809/+ 1.575, 5.008 <0.001
Female sex 0.449 0.249, 0.808 <0.01
DMARDs
1 0.887/mo 0.856, 0.918 <0.001
Extended Cox multiple regression model, with fixed and time-dependent
covariates.
1Time-dependent co-variate
Global Chi square (LR) = 131.45 on 5df (P < 0.001)
CI, confidence interval; DMARDs, disease-modifying anti-rheumatic drugs; ESR,
erythrocyte sedimentation rate; HR, hazard ratio; RA, rheumatoid arthritis
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variables in Table 4). The synergistic effect of increasing
ESR at baseline and a higher triglyceride level is more
than doubled by the impact of hypertension.
In a similar model, adjusted for gender, an increase
in the incidence of CVE was indicated by cumulative
disease activity (AUC DAS28) at six months (hazard
ratio (HR) 1.064, confidence interval (CI) 1.027 to
1,102; P < 0.001) together with the presence of hyper-
tension (HR 3.597, CI 2.028 to 6.380; P = 0.001),
whereas DMARD treatment indicated a reduction (HR
0.891/month, CI 0.862 to 0.921; P < 0.001; data not
shown).
With a focus on pharmacological treatment, DMARDs
given before CVE decreased the incidence of CVE in the
models presented. Treatment with COX-2 inhibitors
before a CVE was a significant predictor of a new CVE
in simple analysis. Adjusting for previous CVE did not
change this relationship (HR 2.121, CI 1.072 to 4.2; P =
0.31). The impact of corticosteroid treatment could not
predict a new CVE when adjusting the models for
inflammatory activity including a model equivalent to
table 4 (data not shown)
Discussion
In patients with newly diagnosed RA followed for five
years, a new CVE was predicted by high disease activity
over time, extra-articular disease and by most of the tra-
ditional CV risk factors, that is, the presence of diabetes
mellitus and/or hypertension at inclusion, and the level
of triglycerides all predicted significantly a new CVE.
Treatment with DMARDs decreased the risk whilst
COX-2 inhibitors appeared to predict a new CVE.
We, and others, have previously shown that inflamma-
tory activity is deleterious for the progression of CVD
[13,15-17] although there are contradicting reports [14].
Most previous publications on CVD in RA are retro-
spective or cross-sectional and studies on inception
cohorts are scarce. In one previous prospective study
from disease onset, CRP at baseline was found to pre-
dict death due to CVD in a cohort comprising patients
with polyarthritis rather th a nR A[ 2 7 ] .I np a t i e n t sw i t h
Figure 1 A new CVE is potentiated by the inflammatory activity and cardiovascular risk factors. Estimated hazard ratio (HR) of a new
cardiovascular event, (CVE), at a given time t during five years follow-up in patients with early rheumatoid arthritis (RA), taking inflammatory
activity (erythrocyte sedimentation rate, ESR) at baseline (T0) and the level of triglycerides in consideration (median values as reference); A)
without and B) with hypertension at baseline. The model also adjusts for gender and disease modifying antirheumatic (DMARD) treatment.
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as measured by carotid intima media thickness, over an
extended follow-up [28]. In the present study, ESR and
CRP at inclusion did not predict future CVE in univari-
ate analyses. However, when evaluated together with CV
risk factors and DMARD treatment, ESR at baseline had
an unfavourable prognostic significance for a new CVE.
Furthermore, cumulative inflammation over time (that
is, AUC of DAS28) could predict a new CVE in simple,
as well as independently in multiple, regression analysis.
Also, a more serious disease, as measured by develop-
ment of extra-articular disease during follow-up, was
associated with a new CVE consistent with previous
reports on the predictive effect of extra-articular disease
and RA-vasculitis [26]. Furthermore, an efficient sup-
pression of disease activity, that is, treatment with
DMARDS within three months following the onset of
rheumatoid disease, significantly reduced the hazard of a
new CVE as did more intensive DMARD treatment over
time; the latter finding also applied to multiple regres-
sion models. It was also apparent that inflammatory
activity is particularly dangerous in patients when com-
bined with the presence of traditional CV risk factors
such as hypertension and hyper-triglyceridaemia. These
results emphasize previous findings by others [17].
Another finding of the present study was that treat-
ment with COX-2 inhibitors was significantly predictive
of a new CVE. Analogous with this, the consumption of
COX-2 inhibitors was recently reported significantly
more often in patients who developed an incident CVD
in a three-year follow-up [29]. Treatment with COX-2
inhibitors during the first years after this study was
initiated would preferably have been administered to
patients with a known increased CVE risk to reduce the
risk of complications such as gastrointestinal bleeding
and water retention with concomitant CV complica-
tions. After rofecoxib was withdrawn in 2004, the oppo-
site situation would be representative; that is, patients
with an increased CV risk would not be treated with
COX-2 inhibitors. After adjustment for a previous CVE,
COX-2-inhibition was, however, still significantly predic-
tive of a new CVE in our cohort.
Corticosteroid treatment appeared to be able to pre-
dict a new CVE according to univariate analyses. How-
ever, when the inflammatory activity was taken into
account, corticosteroid treatment had no statistically sig-
nificant impact on the hazard rate of CVE, implicating
confounding by indication as an explanation for the
results. Analogous to the findings presented, most longi-
tudinal studies have not reported low-dose corticoster-
oid treatment to be a risk factor for CVD in patients
with RA although this is still somewhat controversial
[30]. We, and others, have reported a decreased risk for
a new CVE following treatment with corticosteroids
[13,16]. An attractive explanation would be that corti-
costeroid treatment reduces the deleterious disease
activity by suppressing the inflammatory response.
Although corticosteroids may have pro-atherogenic
effects, as shown in patients with SLE [31], the net effect
on CVD progression would be positive. A recent histo-
logical study of coronary artery tissue showed more
unstable plaques in patients with RA compared with
controls [32]. One possible pathogenic explanation to a
favourable effect of treatment with corticosteroids would
be a stabilization of such plaques.
W ef o u n dt h a tan e wC V Ew a sp r e d i c t e db ym o s to f
the traditional CV risk factors. This is at variance with
most previous reports in which traditional risk factors
have usually not been found to be of major importance
for the development of CVD in patients with RA
[5,10,12,13]. Hypertension increased the hazard ratio,
both when measured by ongoing anti-hypertensive treat-
ment and as raised current systolic and diastolic blood
pressure. On this point, our data confirm previous retro-
spective studies [3,12,13,16,17,33] that have shown
hypertension to be a significant predictor of a first CVE
or death due to CVD. Over time, the treatment of
hypertension had increased significantly at T5. In con-
trast, blood pressure at inclusion was higher than at the
end of the follow-up period, probably reflecting the
greater disease activity at disease onset, or as a result of
anti-hypertensive treatment, and/or a better control of
the blood pressure due to a stringent follow-up.
Diabetes mellitus was also significantly predictive of a
new CVE. The influence of diabetes on future CVD has
not been demonstrated in previous studies
[5,10,12,13,16] although insulin resistance has been
reported in RA patients [34,35]. In the QUEST-RA
study, diabetes emerged as an independent risk factor in
multivariate analyses but only for stroke [36].
Regarding hyperlipidaemia, statin treatment at inclu-
sion (which can be considered a proxy for pre-existing
hyperlipidaemia) increased the CV risk whilst a high
HDL level decreased the hazard at statistical levels that
were close to significance. In accordance with most pre-
vious studies, the level of total cholesterol was not pre-
dictive of CVD in this RA cohort. Dyslipidaemia, that is,
a disturbed ratio of S-LDL/HDL cholesterol, may be
relevant for the development of CVD in RA patients
and appears to be dependent on higher disease activity
[37-41]. In the present study, a higher triglyceride level
increased the risk of CVE independent of sex, disease
activity, anti-rheumatic treatment and hypertension.
This is not consistent with previous studies
[33,38,39,42]. In patients with SLE, hyper-triglyceridae-
mia is regularly reported as part of the lipid pattern
commonly denoted as “lupus dyslipoproteinaemia” and
comprises a decreased HDL level, an increased
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[43]. This pattern is, in SLE patients, associated with
disease activity. One mechanism suggested to be respon-
sible for this pattern is inhibition of lipoproteinlipase
activity. In a previous study on patients with established
RA, we found no increase in the level of triglycerides,
but a relationship between lipoproteinlipase and inflam-
matory activity [44]. It is possible that the size of the
patient cohort and the prospective design of this study
is better equipped to reveal any important role for tri-
glyceridaemia in atherogenesis in addition to RA. How-
ever, the level of LPL was not evaluated in this study.
The proportion of patients who smoked decreased
over time. Smoking is a well-known risk factor for CVD
morbidity and mortality in the general population, but
was not a statistically significant independent predictor
for a CVE in this prospective cohort of patients with
RA. Only a few studies have reported an obvious nega-
tive impact of smoking on CVD in RA patients [12].
This is probably not due to smoking being less harmful
in these patients but rather to its relatively small contri-
bution to the total CV risk in patients affected with
chronic inflammation [12].
Additionally, the mean BMI decreased significantly
during the first five years of disease. Although most of
the patients were adequately treated, with a mean
DAS28 of 3.2 after five years, the decreased BMI may be
a reflection of the continuing inflammation in RA lead-
ing to a certain degree of rheumatological cachexia [45].
In previous studies, a low, rather than a high, BMI has
been associated with an increased risk of death due to
CVD in patients with RA [46,47]. However, in these
patients with early RA, the BMI did not show up as a
significant predictor for a new CVE.
No association between the presence of RF or ACPA
and future CVE was found. This is in contrast to a
recent report [48] in which it was claimed that ischae-
m i ch e a r td i s e a s ei sm o r ef r e q u e n ti nR F -o rA C P A -
positive RA patients. However, the patient group in that
study was hospital-based implying a more severe disease
state than was present in our community based patient
cohort. Furthermore, their cohort was not inceptional,
with a mean disease duration over 10 years. The lack of
association between PTPN22 polymorphism and future
CVE was on the other hand in keeping with a recent
study [49].
There are several strengths of the present study. First,
the patient group comprises a large regional cohort and
the prospective design involves few physicians at each
rheumatology centre. In Sweden, essentially all patients
with newly diagnosed RA are referred to a specialist.
Thus, the results for the present cohort can be regarded
to be general and, therefore, applicable to all patients
with early RA. Furthermore, since only patients with
very early disease were included, left censorship was
avoided. Furthermore, repeated measurement of the
parameters associated with inflammation made it possi-
ble to take variability in disease activity into account.
Conversely, a limitation is the observational nature of
this study with a risk of confounding by indication
regarding the effects of pharmacological treatment. We
tried to adjust for that by using multiple regression
modelling in the statistical analyses when evaluating
potential predictors of CVE. Another limitation is the
relatively small number of events which restricts the
estimation of possible multiple Cox models.
In the present prospective study evaluating risk factors
for progression of CVE co-morbidity in patients with a
recent onset of RA, we were able to show that the inflam-
matory status, both at disease onset and accumulated
over time, was a strong predictor of a new CVE, with
implications also for disease severity, measured as extra-
articular disease. Furthermore, traditional risk factors and
disease activity appeared to potentiate each other. Our
data confirm the cardio-protective effect of disease modi-
fying anti-rheumatic treatment. There were also implica-
tions of a harmful effect of Cox-2-inhibitions. Possibly
due to the size and prospective design of this study, it
was possible to show that most traditional risk factors for
CVD are also of importance in early RA. In previous stu-
dies, their relative contribution to the total risk may have
been concealed by the strong influence of inflammation.
Because traditional CV risk factors are modifiable, a large
effort should be made towards their prevention and treat-
ment, in addition to the fundamental suppression of dis-
ease activity, when monitoring the care of patients with
early RA. Our prospective data may add to the accumu-
lated knowledge in future development of guidelines for
the prevention of CVD in patients with rheumatic dis-
ease, work that is already ongoing in several countries
and through international collaboration [50].
Conclusions
In conclusion, we found that the progression of a new
CVE in early RA was predicted by traditional CV risk
factors, that is, the presence of diabetes mellitus and/or
hypertension at inclusion, and the level of triglycerides,
and was potentiated by high disease activity at inclusion
and accumulated over time. Our data confirm the car-
dio-protective effect of disease modifying anti-rheumatic
treatment. Given the current state of knowledge, it is
important to suppress disease activity and great effort
should be made to optimize the prevention and treat-
ment of traditional CV risk factors in patients with RA.
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